Sign In
Last checked at 
29 Dec 2017 07:00
Blocklisting Six Monthly Return
Β
London: Friday, December 29, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
Β
1. | Name of applicant: Β | Hutchison China MediTech Limited | |
2. | Name of scheme: Β | Hutchison China MediTech Limited Share Option Schemes Β | |
3. | Period of return: Β | From June 29, 2017 to December 28, 2017 Β | |
4. | Balance under scheme from previous return: Β | 1,329,927 ordinary shares of US$1 each | |
5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: Β | Nil | |
6. | Number of securities issued/allotted under scheme during period: Β | 24,928 ordinary shares of US$1 each | |
7. | Balance under scheme not yet issued/allotted at end of the period: Β | 1,304,999 ordinary shares of US$1 each | |
8. | Number and class of securities originally listed and the date of admission: Β | 2,560,606 ordinary shares of US$1 each admitted on June 26, 2007 | |
9. | Total number of securities in issue at the end of the period: Β | 66,447,037 ordinary shares of US$1 each | |
Name of contact: Β | Christian Hogg | ||
Address of contact: Β | 21/F., Hutchison House, 10 Harcourt Road, HongΒ Kong Β | ||
Telephone number of contact: Β | +852 2121 8200 | ||
Β
Β
About Chi-Med
Β
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Β
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
Β
Β
CONTACTS
Β
Investor Enquiries | ||
Mark Lee, Senior Vice President, Corporate Finance & Development | +852Β 2121Β 8200 | |
U.K. & International Media Enquiries | ||
Anthony Carlisle, Citigate Dewe Rogerson | +44Β 7973Β 611Β 888 (Mobile) | anthony.carlisle@cdrconsultancy.co.uk |
U.S. Based Media Enquiries | ||
Brad Miles, BMC Communications | +1Β (917)Β 570Β 7340 (Mobile) | bmiles@bmccommunications.com |
Susan Duffy, BMC Communications | +1Β (917)Β 499Β 8887 (Mobile) | sduffy@bmccommunications.com |
Investor Relations | ||
Matt Beck, The Trout Group | +1Β (917)Β 415Β 1750 (Mobile) | mbeck@troutgroup.com |
David Dible, Citigate Dewe Rogerson | +44Β 7967Β 566Β 919 (Mobile) | david.dible@citigatedewerogerson.com |
Panmure Gordon (UK) Limited | ||
Richard Gray / Andrew Potts | +44Β (20)Β 7886Β 2500 |
Β
Follow the stocks
